{"id":60017,"name":"CLENE NANOMEDICINE","slug":"clene-nanomedicine","state":"MD","country":"United States of America","description":"Biopharmaceutical company treating neurodegenerative diseases.","totalSpending":55000,"filings":8,"yearlySpending":[{"year":2024,"income":50000},{"year":2025,"income":5000}],"issues":["HCR","MED","BUD","MMM"],"firms":["THE MIZEUR GROUP, LLC"],"lobbyists":["HEATHER MIZEUR"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Food & Drug Administration (FDA)"],"sampleDescriptions":["Navigating policy issues that surround FDA approval of company's treatments for neurodegenerative diseases (like ALS, MS, and Parkinson's) through restoration and protection of nueronal health and fun","Navigating policy issues that surround FDA approval of company's treatments for neurodegenerative diseases (like ALS, MS, and Parkinson's) through restoration and protection of nueronal health and fun","Navigating policy issues that surround FDA approval of company's treatments for neurodegenerative diseases (like ALS, MS, and Parkinson's) through restoration and protection of nueronal health and fun","Navigating policy issues that surround FDA approval of company's treatments for neurodegenerative diseases (like ALS, MS, and Parkinson's) through restoration and protection of nueronal health and fun","Gaining insight on Congressional intent regarding Accelerated Approval statute 21 USC SECTION 356 and inconsistencies with 21 CFR Section 314."],"years":[2024,2025]}